AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2017
Feb 3, 2017
29828_dirs_2017-02-03_2927ce68-2aa1-44eb-917d-294a6006d384.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2017-02-01
Reporting Person: MARTIN JOHN C (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-01 | Common Stock | M | 73333 | $21.575 | Acquired | 3204429 | Direct |
| 2017-02-01 | Common Stock | S | 73333 | $72.574 | Disposed | 3131096 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-01 | Non-qualified Stock Option (Right to Buy) | $21.575 | M | 73333 | Disposed | 2018-01-30 | Common Stock (73333) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013.
F3: Sale prices reported for the transactions reported here range from $72.09 to $72.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.